Depo-Provera Lawsuit Update 2026 : Pfizer’s Daubert Motion and What It Means for 3,790 Meningioma Victims

Pfizer is fighting back. In a pivotal move filed on April 22, 2026, the pharmaceutical giant submitted a motion in the Depo-Provera meningioma MDL — formally known as In Re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140 — asking Judge M. Casey Rodgers of the Northern District of Florida to exclude critical expert testimony before any of the nearly 3,790 active cases can reach a jury. The outcome of this battle will shape the future of one of the most significant pharmaceutical mass tort cases of 2026.

If you received Depo-Provera injections and were later diagnosed with a meningioma brain tumor, this update directly affects your case timeline and potential compensation. Use our free Depo-Provera settlement calculator to get an instant estimate of what your claim may be worth.

Pfizer’s Daubert Motion: What They’re Actually Arguing

Pfizer’s April 2026 motion targets four specific scientific opinions that plaintiffs’ experts plan to present to juries. Understanding what Pfizer is challenging — and why — reveals the real pressure points in this litigation.

• Claim 1 — New tumor creation: Pfizer disputes that Depo-Provera can generate brand-new meningioma tumors in previously healthy tissue, arguing the drug only promotes growth of pre-existing tumors.
• Claim 2 — Short-term use risk: Pfizer contests expert opinions that less than one year of use — or even a single injection — can cause meningioma, noting that six of nine post-2024 studies either excluded short-term users or reported no results for them.
• Claim 3 — Lingering risk after stopping: Pfizer challenges testimony that meningioma risk persists more than two years after a woman stops the drug, pointing to data showing risk declines as time since last injection increases.
• Claim 4 — Spinal and malignant tumors: Pfizer disputes the connection between Depo-Provera and spinal or malignant meningiomas, where the scientific evidence is less established.

Here is the critical detail: Pfizer is not arguing the drug is completely safe. The company concedes that prolonged, current use can cause pre-existing benign meningiomas to grow large enough to become symptomatic and diagnosed. That admission follows Pfizer into every courtroom.

What Is a Daubert Hearing and Why Does This One Matter So Much?

Named after the landmark U.S. Supreme Court case Daubert v. Merrell Dow Pharmaceuticals, a Daubert hearing requires federal judges to serve as scientific gatekeepers. The judge does not evaluate whether an expert is qualified — she evaluates whether the methodology underlying the expert’s opinion is sufficiently reliable to be heard by a jury.

In a massive MDL like the Depo-Provera litigation, a defense victory at the Daubert stage carries potentially catastrophic consequences for plaintiffs. If Judge Rodgers rules that plaintiffs cannot present expert testimony on general causation, she could effectively end thousands of cases simultaneously without a single trial.

The general causation hearings are now officially scheduled for June 24–26, 2026, after being rescheduled from late May. These three days will determine whether plaintiffs’ expert testimony survives judicial scrutiny and whether the first pilot bellwether trials can proceed in December 2026 as planned.

The Science Pfizer Cannot Escape: FDA Label Change and the Frey Study

Pfizer walked into this litigation with a serious structural disadvantage that no Daubert motion can erase. In December 2025, the FDA updated Depo-Provera’s official label to require a meningioma warning: “Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.”

The FDA’s own label change is the scientific ground Pfizer must now defend from. The company cannot simultaneously argue that the science is too weak to reach a jury while its own product carries an FDA-mandated meningioma warning.

Adding further scientific weight to plaintiffs’ position is the recently published Frey study — a methodological upgrade from the earlier Roland study that triggered this litigation. Where Roland was based on only eight exposed cases, Frey uses 212 cases and 848 matched controls, applies a comparison group of other hormonal contraceptives, and introduces lag periods of up to four years to account for tumor latency. Courts at Daubert look specifically for methodological soundness — and Frey delivers exactly that.

Depo-Provera MDL by the Numbers: May 2026

• 3,790 unique plaintiffs enrolled in the federal MDL as of March 6, 2026
• MDL No. 3140 — Northern District of Florida, Pensacola Division, before Judge M. Casey Rodgers
• Monthly Case Management Conferences throughout 2026 — next CMC May 15, 2026
• Lead Counsel: Christopher Seeger (Seeger Weiss); Co-Chair Executive Committee: Tracy Finken (Anapol Weiss) — reappointed March 20, 2026
• First bellwether trials targeted for December 2026
• Meningioma warning labels adopted in other countries years before the U.S. — raising questions about Pfizer’s delayed U.S. action

Who Qualifies for a Depo-Provera Meningioma Lawsuit?

• You received Depo-Provera (medroxyprogesterone acetate) injections — typically for at least 12 months (shorter-term cases also being evaluated)
• You were diagnosed with an intracranial meningioma — including cranial meningioma, arachnoid tumor, or skull base meningioma
• Your Depo-Provera use predates your meningioma diagnosis
• You are filing within the applicable statute of limitations — typically 2–4 years from diagnosis or discovery of the link

Cases involving brain surgery, permanent neurological deficits, hearing loss, vision impairment, or significant impact on daily functioning command the highest settlement values. Explore our dedicated Depo-Provera lawsuit guide for complete eligibility details.

Depo-Provera Lawsuit Settlement Amounts 2026

No global settlement has been reached as of May 2026. Based on analogous pharmaceutical mass torts and meningioma injury severity, attorneys are projecting:

• Base tier — monitoring only, limited impairment: $100,000 – $300,000
• Mid tier — radiation therapy, moderate neurological symptoms: $400,000 – $800,000
• High-value — craniotomy, permanent deficits (hearing loss, vision loss, cognitive impairment): $800,000 – $1,500,000+

Frequently Asked Questions: Depo-Provera Lawsuit 2026

What Should You Do Right Now?

The June 2026 Daubert hearings represent a turning point in this litigation. Here is what matters for anyone who used Depo-Provera and later developed a meningioma:

1. Don’t wait for the Daubert ruling. Filing now gets you into the MDL before any potential deadline changes.
2. Gather your medical records. Depo-Provera injection records, meningioma diagnosis documentation, surgical records, and neurological assessments are all critical.
3. Get a free case evaluation today. No upfront cost, no fee unless you win.